Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 272

1.

Electric generation and ratcheted transport of contact-charged drops.

Cartier CA, Graybill JR, Bishop KJM.

Phys Rev E. 2017 Oct;96(4-1):043101. doi: 10.1103/PhysRevE.96.043101. Epub 2017 Oct 2.

PMID:
29347598
2.

Mechanical Response of Thermally Annealed Nafion Thin Films.

Frieberg BR, Page KA, Graybill JR, Walker ML, Stafford CM, Stafford GR, Soles CL.

ACS Appl Mater Interfaces. 2016 Dec 7;8(48):33240-33249. Epub 2016 Nov 23.

PMID:
27934151
3.

A murine model of Cryptococcus gattii meningoencephalitis.

Thompson GR 3rd, Wiederhold NP, Najvar LK, Bocanegra R, Kirkpatrick WR, Graybill JR, Patterson TF.

J Antimicrob Chemother. 2012 Jun;67(6):1432-8. doi: 10.1093/jac/dks060. Epub 2012 Feb 29.

4.

Adiaspiromycosis causing respiratory failure and a review of human infections due to Emmonsia and Chrysosporium spp.

Anstead GM, Sutton DA, Graybill JR.

J Clin Microbiol. 2012 Apr;50(4):1346-54. doi: 10.1128/JCM.00226-11. Epub 2012 Jan 18. Review.

5.
6.

Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani.

Wiederhold NP, Najvar LK, Bocanegra R, Graybill JR, Patterson TF.

Antimicrob Agents Chemother. 2010 Mar;54(3):1055-9. doi: 10.1128/AAC.01445-09. Epub 2010 Jan 11.

7.

Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america.

Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, Harrison TS, Larsen RA, Lortholary O, Nguyen MH, Pappas PG, Powderly WG, Singh N, Sobel JD, Sorrell TC.

Clin Infect Dis. 2010 Feb 1;50(3):291-322. doi: 10.1086/649858.

8.

Consensus statement on the management of invasive candidiasis in Intensive Care Units in the Asia-Pacific Region.

Hsueh PR, Graybill JR, Playford EG, Watcharananan SP, Oh MD, Ja'alam K, Huang S, Nangia V, Kurup A, Padiglione AA.

Int J Antimicrob Agents. 2009 Sep;34(3):205-9. doi: 10.1016/j.ijantimicag.2009.03.014. Epub 2009 May 5.

PMID:
19409759
9.

Inhaled voriconazole for prevention of invasive pulmonary aspergillosis.

Tolman JA, Wiederhold NP, McConville JT, Najvar LK, Bocanegra R, Peters JI, Coalson JJ, Graybill JR, Patterson TF, Williams RO 3rd.

Antimicrob Agents Chemother. 2009 Jun;53(6):2613-5. doi: 10.1128/AAC.01657-08. Epub 2009 Mar 16.

10.

The north and south of candidemia: Issues for Latin America.

Colombo AL, Thompson L, Graybill JR.

Drugs Today (Barc). 2008 Sep;44 Suppl A:1-34. Review.

PMID:
18810276
11.

Posaconazole as salvage treatment of invasive fungal infections in patients with underlying renal impairment.

Hachem RY, Langston AA, Graybill JR, Perfect JR, Pedicone LD, Patino H, Raad II.

J Antimicrob Chemother. 2008 Dec;62(6):1386-91. doi: 10.1093/jac/dkn401. Epub 2008 Oct 3.

PMID:
18835806
12.

Posaconazole as salvage therapy in patients with invasive fungal infections after solid organ transplant.

Alexander BD, Perfect JR, Daly JS, Restrepo A, Tobón AM, Patino H, Hardalo CJ, Graybill JR.

Transplantation. 2008 Sep 27;86(6):791-6. doi: 10.1097/TP.0b013e3181837585.

PMID:
18813103
13.

Evaluation of aminocandin and caspofungin against Candida glabrata including isolates with reduced caspofungin susceptibility.

Brzankalski GE, Najvar LK, Wiederhold NP, Bocanegra R, Fothergill AW, Rinaldi MG, Pattterson TF, Graybill JR.

J Antimicrob Chemother. 2008 Nov;62(5):1094-100. doi: 10.1093/jac/dkn304. Epub 2008 Jul 25.

14.

Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria.

Segal BH, Herbrecht R, Stevens DA, Ostrosky-Zeichner L, Sobel J, Viscoli C, Walsh TJ, Maertens J, Patterson TF, Perfect JR, Dupont B, Wingard JR, Calandra T, Kauffman CA, Graybill JR, Baden LR, Pappas PG, Bennett JE, Kontoyiannis DP, Cordonnier C, Viviani MA, Bille J, Almyroudis NG, Wheat LJ, Graninger W, Bow EJ, Holland SM, Kullberg BJ, Dismukes WE, De Pauw BE.

Clin Infect Dis. 2008 Sep 1;47(5):674-83. doi: 10.1086/590566. Review.

15.

Voriconazole in the treatment of fungal eye infections: a review of current literature.

Hariprasad SM, Mieler WF, Lin TK, Sponsel WE, Graybill JR.

Br J Ophthalmol. 2008 Jul;92(7):871-8. doi: 10.1136/bjo.2007.136515. Review.

PMID:
18577634
16.

Assessment of Aspergillus fumigatus burden in pulmonary tissue of guinea pigs by quantitative PCR, galactomannan enzyme immunoassay, and quantitative culture.

Vallor AC, Kirkpatrick WR, Najvar LK, Bocanegra R, Kinney MC, Fothergill AW, Herrera ML, Wickes BL, Graybill JR, Patterson TF.

Antimicrob Agents Chemother. 2008 Jul;52(7):2593-8. doi: 10.1128/AAC.00276-08. Epub 2008 May 12.

17.

Therapeutic and prophylactic efficacy of aminocandin (IP960) against disseminated candidiasis in mice.

Najvar LK, Bocanegra R, Wiederhold NP, Lambros C, Najarian N, Patterson TF, Graybill JR.

Clin Microbiol Infect. 2008 Jun;14(6):595-600. doi: 10.1111/j.1469-0691.2008.01994.x. Epub 2008 Apr 5.

18.

Fungicidal versus Fungistatic: what's in a word?

Lewis JS 2nd, Graybill JR.

Expert Opin Pharmacother. 2008 Apr;9(6):927-35. doi: 10.1517/14656566.9.6.927. Review.

PMID:
18377336
19.

Assessment of serum (1->3)-beta-D-glucan concentration as a measure of disease burden in a murine model of invasive pulmonary aspergillosis.

Wiederhold NP, Najvar LK, Vallor AC, Kirkpatrick WR, Bocanegra R, Molina D, Olivo M, Graybill JR, Patterson TF.

Antimicrob Agents Chemother. 2008 Mar;52(3):1176-8. Epub 2007 Dec 26.

20.

Antimicrobial resistance prevention initiative--an update: proceedings of an expert panel on resistance.

Moellering RC Jr, Graybill JR, McGowan JE Jr, Corey L; American Society for Microbiology.

Am J Infect Control. 2007 Nov;35(9):S1-23; quiz S24-6. Review.

PMID:
17980231
21.

Therapeutic efficacy of caspofungin alone and in combination with amphotericin B deoxycholate for coccidioidomycosis in a mouse model.

González GM, González G, Najvar LK, Graybill JR.

J Antimicrob Chemother. 2007 Dec;60(6):1341-6. Epub 2007 Oct 12.

PMID:
17934204
22.

Antimicrobial resistance prevention initiative--an update: proceedings of an expert panel on resistance.

Moellering RC Jr, Graybill JR, McGowan JE Jr, Corey L.

Am J Med. 2007 Jul;120(7):S4-25; quiz S26-8.

PMID:
17602911
23.

Posaconazole therapy for chronic refractory coccidioidomycosis.

Stevens DA, Rendon A, Gaona-Flores V, Catanzaro A, Anstead GM, Pedicone L, Graybill JR.

Chest. 2007 Sep;132(3):952-8. Epub 2007 Jun 15.

PMID:
17573510
24.

New guinea pig model of Cryptococcal meningitis.

Kirkpatrick WR, Najvar LK, Bocanegra R, Patterson TF, Graybill JR.

Antimicrob Agents Chemother. 2007 Aug;51(8):3011-3. Epub 2007 Jun 11.

25.

Aerosolized nanostructured itraconazole as prophylaxis against invasive pulmonary aspergillosis.

Alvarez CA, Wiederhold NP, McConville JT, Peters JI, Najvar LK, Graybill JR, Coalson JJ, Talbert RL, Burgess DS, Bocanegra R, Johnston KP, Williams RO 3rd.

J Infect. 2007 Jul;55(1):68-74. Epub 2007 Mar 13.

PMID:
17360039
26.

In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera.

Wiederhold NP, Najvar LK, Bocanegra R, Molina D, Olivo M, Graybill JR.

Antimicrob Agents Chemother. 2007 May;51(5):1616-20. Epub 2007 Feb 16.

27.

Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection.

Skiest DJ, Vazquez JA, Anstead GM, Graybill JR, Reynes J, Ward D, Hare R, Boparai N, Isaacs R.

Clin Infect Dis. 2007 Feb 15;44(4):607-14. Epub 2007 Jan 17.

PMID:
17243069
28.

Standardization of an experimental murine model of invasive pulmonary aspergillosis.

Sheppard DC, Graybill JR, Najvar LK, Chiang LY, Doedt T, Kirkpatrick WR, Bocanegra R, Vallor AC, Patterson TF, Filler SG.

Antimicrob Agents Chemother. 2006 Oct;50(10):3501-3.

29.

In-vivo dynamic deformation of the mitral valve anterior leaflet.

Sacks MS, Enomoto Y, Graybill JR, Merryman WD, Zeeshan A, Yoganathan AP, Levy RJ, Gorman RC, Gorman JH 3rd.

Ann Thorac Surg. 2006 Oct;82(4):1369-77.

PMID:
16996935
30.

Coccidioidomycosis.

Anstead GM, Graybill JR.

Infect Dis Clin North Am. 2006 Sep;20(3):621-43. Review.

PMID:
16984872
31.

Clinical research in the lay press: irresponsible journalism raises a huge dose of doubt.

Anaissie EJ, Segal BH, Graybill JR, Arndt C, Perfect JR, Kleinberg M, Pappas P, Benjamin D, Rubin R, Aberg JA, Adderson EE, Adler-Shohet FC, Akan H, Akova M, Almyroudis NG, Alexander BD, Andes D, Arrieta A, Baddley JW, Barron MA, Belzberg H, Boucher HW, Boyce TG, Casadevall A, Chandrasekar PH, Cleary JD, Cordonnier C, Cornely OA, Cuenca-Estrella M, Daly JS, Daoura N, Denning DW, dePauw B, de Repentigny L, Dignani MC, Dismukes WE, Donnelly JP, Donowitz GR, Dupont B, Drusano G, Ellis M, Espinel-Ingroff A, Fishman JA, Fleming R, Forrest G, Ghannoum M, Goldman M, Grazziutti M, Greene JN, Greenberg RN, Gubbins PO, Hadley S, Herbrecht R, Hiemenz JW, Hope W, Hospenthal DR, Husain S, Ito JI, Jacobson RM, Johnson M, Keating MR, Kett DH, Knapp K, Kontoyiannis DP, Krcmery VC, Larsen R, Laverdiere M, Ljungman P, Lortholary O, Maertens J, Marriott D, Mattiuzzi G, McGinnis MR, Morris M, Nucci M, Odds FC, Pankey GA, Patterson T, Pfaller M, Razonable RR, Reboli AC, Rinaldi MG, Roberts GD, Rodriguez Tudela JL, Rotstein C, Ruhnke M, Schuster M, Shoham S, Sia IG, Siebel N, Silviera F, Singh N, Sobel J, Solomkin JS, Sorrell TC, Steinbach WJ, Temesgen Z, Tortorano A, Vartivarian S, VerWeij P, Viscoli C, Viviani MA, Walker RC, Wheat JL, Wiley J, Williamson P, Wingard JR, Yu VL, Zaoutis T.

Clin Infect Dis. 2006 Oct 15;43(8):1031-9. Epub 2006 Sep 13. No abstract available. Erratum in: Clin Infect Dis. 2007 Mar 15;44(6):894.

PMID:
16983616
32.

In vitro pharmacodynamics of anidulafungin and caspofungin against Candida glabrata isolates, including strains with decreased caspofungin susceptibility.

Cota J, Carden M, Graybill JR, Najvar LK, Burgess DS, Wiederhold NP.

Antimicrob Agents Chemother. 2006 Nov;50(11):3926-8. Epub 2006 Aug 28.

33.
34.

Salvage treatment of histoplasmosis with posaconazole.

Restrepo A, Tobón A, Clark B, Graham DR, Corcoran G, Bradsher RW, Goldman M, Pankey G, Moore T, Negroni R, Graybill JR.

J Infect. 2007 Apr;54(4):319-27. Epub 2006 Jul 7.

PMID:
16824608
35.

Disruption of a nonribosomal peptide synthetase in Aspergillus fumigatus eliminates gliotoxin production.

Cramer RA Jr, Gamcsik MP, Brooking RM, Najvar LK, Kirkpatrick WR, Patterson TF, Balibar CJ, Graybill JR, Perfect JR, Abraham SN, Steinbach WJ.

Eukaryot Cell. 2006 Jun;5(6):972-80.

36.

Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections.

Raad II, Graybill JR, Bustamante AB, Cornely OA, Gaona-Flores V, Afif C, Graham DR, Greenberg RN, Hadley S, Langston A, Negroni R, Perfect JR, Pitisuttithum P, Restrepo A, Schiller G, Pedicone L, Ullmann AJ.

Clin Infect Dis. 2006 Jun 15;42(12):1726-34. Epub 2006 May 8.

PMID:
16705579
37.

Control of a Candida glabrata prosthetic endovascular infection with posaconazole.

Anstead GM, Martinez M, Graybill JR.

Med Mycol. 2006 May;44(3):273-7.

PMID:
16702108
38.

Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions.

Raad II, Hachem RY, Herbrecht R, Graybill JR, Hare R, Corcoran G, Kontoyiannis DP.

Clin Infect Dis. 2006 May 15;42(10):1398-403. Epub 2006 Apr 11.

PMID:
16619151
39.

In vivo efficacy of aerosolized nanostructured itraconazole formulations for prevention of invasive pulmonary aspergillosis.

Hoeben BJ, Burgess DS, McConville JT, Najvar LK, Talbert RL, Peters JI, Wiederhold NP, Frei BL, Graybill JR, Bocanegra R, Overhoff KA, Sinswat P, Johnston KP, Williams RO 3rd.

Antimicrob Agents Chemother. 2006 Apr;50(4):1552-4.

40.

Caspofungin and liposomal amphotericin B therapy of experimental murine scedosporiosis.

Bocanegra R, Najvar LK, Hernandez S, McCarthy DI, Graybill JR.

Antimicrob Agents Chemother. 2005 Dec;49(12):5139-41.

41.

Retinal function assessed by ERG before and after induction of ocular aspergillosis and treatment by the anti-fungal, micafungin, in rabbits.

Harrison JM, Glickman RD, Ballentine CS, Trigo Y, Pena MA, Kurian P, Najvar LK, Kumar N, Patel AH, Sponsel WE, Graybill JR, Lloyd WC 3rd, Miller MM, Paris G, Trujillo F, Miller A, Melendez R.

Doc Ophthalmol. 2005 Jan;110(1):37-55.

PMID:
16249956
42.

Voriconazole for candidosis: an important addition?

Graybill JR.

Lancet. 2005 Oct 22-28;366(9495):1413-4. No abstract available.

PMID:
16243074
43.

Activity of posaconazole in the treatment of central nervous system fungal infections.

Pitisuttithum P, Negroni R, Graybill JR, Bustamante B, Pappas P, Chapman S, Hare RS, Hardalo CJ.

J Antimicrob Chemother. 2005 Oct;56(4):745-55. Epub 2005 Aug 31.

PMID:
16135526
44.

Refractory coccidioidomycosis treated with posaconazole.

Anstead GM, Corcoran G, Lewis J, Berg D, Graybill JR.

Clin Infect Dis. 2005 Jun 15;40(12):1770-6. Epub 2005 May 13.

PMID:
15909265
45.

Antifungal therapy of experimental cerebral phaeohyphomycosis due to Cladophialophora bantiana.

Al-Abdely HM, Najvar LK, Bocanegra R, Graybill JR.

Antimicrob Agents Chemother. 2005 May;49(5):1701-7.

46.

Antifungal therapy of murine Aspergillus terreus infection.

Graybill JR, Hernandez S, Bocanegra R, Najvar LK.

Antimicrob Agents Chemother. 2004 Oct;48(10):3715-9.

47.

Alternatives to amphotericin B for Candida rugosa infection.

Hernandez S, Gonzalez GM, McCarthy DI, Colombo AL, Najvar LK, Bocanegera R, Graybill JR.

J Antimicrob Chemother. 2004 Aug;54(2):477-80. Epub 2004 Jun 23.

PMID:
15215225
48.

Posaconazole therapy of disseminated phaeohyphomycosis in a murine model.

Graybill JR, Najvar LK, Johnson E, Bocanegra R, Loebenberg D.

Antimicrob Agents Chemother. 2004 Jun;48(6):2288-91.

49.

Efficacies of amphotericin B (AMB) lipid complex, AMB colloidal dispersion, liposomal AMB, and conventional AMB in treatment of murine coccidioidomycosis.

González GM, Tijerina R, Najvar LK, Bocanegra R, Rinaldi MG, Graybill JR.

Antimicrob Agents Chemother. 2004 Jun;48(6):2140-3.

50.

Supplemental Content

Loading ...
Support Center